Rural Health
News by Topic: Infectious diseases
Jan 7, 2026 - Notice from the Health Resources and Services Administration (HRSA) seeking comments on an information collection regarding a form related to the COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) rural payment reporting activities. The information collection is used to assess if statutory and programmatic requirements are met; conduct audits; report on findings with respect to the disbursements of PRF and ARP Rural payments; and for the program evaluation. Comments are due by February 6, 2026.
Source: Federal Register
CDC: Agency Forms Undergoing Paperwork Reduction Act Review
Federal Register
Dec 22, 2025 - The Centers for Medicare & Medicaid Services (CMS) is allowing an additional 30 days for comments on a proposed information collection project titled "National Healthcare Safety Network (NHSN) Respiratory Data." This information collection is designed to standardize the data elements collected from across the country regarding the impact of respiratory viruses on healthcare facilities. Comments are due within 30 days of this notice.
Source: Federal Register
Dec 22, 2025 - Notice from the Health Resources and Services Administration (HRSA) seeking comments on an information collection titled "Ending the HIV Epidemic (EHE) Initiative in the U.S. Triannual Report OMB No. 0906-0051—Revision." HRSA proposes to revise a footnote to provide clarity on existing instruction. Comments are due January 21, 2026.
Source: Federal Register
Dec 17, 2025 - Discusses alpha-gal syndrome, a tickborne allergy to red meat and dairy, and the challenges with cattle farming due to the condition. Describes what is still unknown about the condition as well as the higher risk of tick exposures for livestock producers.
Source: KBIA
FDA: Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability
Federal Register
Dec 8, 2025 - The Food and Drug Administration (FDA) has revoked an Emergency Use Authorization issued to Genentech, Inc. (Genentech) for Actemra (tocilizumab). The revocation is effective August 8, 2025.
Source: Federal Register